Allogeneic hematopoietic cell transplantation (alloHCT) in older patients requires the weighing of risks and benefits for this potentially curative treatment while facing age-related limitations. Comprehensive geriatric and quality of life (EORTC QLQ C-30) assessements (CGA/QOL) in addition to disease-specific data were obtained in 108 consecutive patients (≥60 years) pre-HCT, at day +30, +100, and +180. Median follow-up of 106 patients alive at alloHCT was 43.5 months, median age 66 years (range 60-78). Eighty-six (81.2%) had advanced disease risk at HCT and 99 (91.7%) patients received reduced intensity conditioning (RIC). Median PFS was 13.4 months with 38.3% (95% CI: 28.6-47.4) alive and in remission at 2 years; median OS was 15.6 months with 43.9% (95% CI: 34.3-53.4) alive at 2 years. Prognostic factors for PFS were: age: HR 1.084 (95% CI: 1.032-1.137, p = 0.0011); HCT-CI: HR 1.13 (95% CI: 1.001-1.274, p = 0.048); for OS: age: HR 1.08 (95% CI: 1.031-1.139, p = 0.0017), Karnofsky Index: HR 0.97 (95% CI: 0.954-0.996, p = 0.02); EORTC QLQ C-30 fatigue: HR 1.09 (95% CI: 1.004-1.185, p = 0.039); Up-and-Go: HR 3.26 (95% CI: 1.001-10.6, p = 0.049). Follow-up assessments as time-dependent covariates were highly prognostic for OS and PFS. CGA/QOL confer additional prognostic utility in older alloHCT recipients.
Introduction
Hematological malignancies affect mainly patients >60 years [1] . Elderly with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) have a poor prognosis as diseases are more aggressive and treatment fails faster than in younger patients [2] . Clinical guidance of older patients and accurate estimation of the risk/benefit ratio of available therapies is difficult and more so when faced with relevant comorbidities or age-associated impairments.
The age limit for many therapeutic trials in hematology has been <60 years, for allogeneic hematopoietic cell transplantation (alloHCT) even 55 years [3] . While alloHCT may represent the only curative treatment option for many, concerns about high treatment associated morbidity and mortality rates were eminent [4] . However, reduced intensity conditioning (RIC) shows encouraging results for alloHCT. Data showed a disease-free survival approaching 50% at 1 year in elderly patients with AML or MDS under RIC with Fludarabine, BCNU and Melphalan (FBM) [5] [6] [7] [8] . Pohlen et al. published retrospective data on AML/MDS patients above 60 years that showed excellent survival data in line with previously published reports [9] . Due to the promising results of large retrospective studies on a rapidly growing patient cohort >70 years that has been successfully transplanted since 2000 [10, 11] , alloHCT has been increasingly understood as feasible and effective.
Gratwohl defined the EBMT risk score in 2012 [12] including the most relevant disease-specific aspects, as well as the patients' age. Further optimized risk stratification and standardization of selection processes may benefit patients and physicians.
Comprehensive geriatric assessments (CGA) provide a method of assessment of older patients, of predicting morbidity and mortality, and uncovering problems relevant to care [13] . We had previously shown that CGA in conjunction with QOL is feasible and results in a high degree of satisfaction in elderly patients with MDS and AML [14] . In preliminary evaluations of HCT patients, a number of items revealed a strong prognostic value [15] . Analyses uncovered compromised performance status as the most significant negative parameter for OS, prompting our efforts to define more precisely what physicians may consider "performance status" and to prospectively evaluate a CGA/QOL [16] . Next, we showed that CGA/QOL was readily feasible in older MDS/AML patients undergoing various treatment options and that it included a number of potential prognostic factors, first and foremost, performance status and of the EORTC-QLQ C30 the item fatigue [17] .
Building on our previous work, we wanted to assess the prognostic value of impairments identified by CGA/QOL for progression-free survival (PFS) and overall survival (OS) among RIC alloHCT recipients and describe nonrelapse mortality (NRM), as well as the outcomes of serial post-transplant assessments.
Subjects and methods
This was a prospective observational prognostic factor study including all consecutive patients meeting the inclusion criteria: patients ≥60 years with myeloid neoplasias planned for alloHCT. One hundred and eight consecutive patients with myeloid malignancies were assessed at the following time points: pre HCT, day +30, +100, +180. All investigations were approved by the local ethics committee and institutional review board, and all patients gave their informed consent.
CGA/QOL (detailed in Supplementary Data) incorporated EORTC QLQ-C30 [14, 18, 19] , Performance status [20, 21] , German Short Form Resilience [22] , Mini Mental State Examination (MMSE) [23] , Timed Up-and-Go [24] , Activities of Daily Living (ADL) and Instrumental ADL [13, [25] [26] [27] Comorbidities [28] [29] [30] [31] , Mini Nutritional Assessment [32] .
We included as disease-specific variables: white blood cell count (WBC), lactate dehydrogenase (LDH), cytogenetic risk group, disease risk as described before [33] , and the EBMT risk score [12] .
Statistical analyses
Data were analyzed using SAS software version 9.2. (SAS Institute Inc, Cary, NC). The primary endpoint was PFS, secondary endpoints were OS and non-relapse mortality (NRM).
Sample size calculations were based on the primary objective to assess the prognostic impact of baseline CGA/ QOL on PFS and aimed at detecting a hazard ratio (HR) of 2.5 with a power of 80% when comparing risk groups. Considering that the distribution of patients may not necessarily result in risk groups of equal size (but e.g., 30:70) and moderate correlations among risk factors (variance inflation factor of 1.3), we calculated a required effective sample size of 58 events. The required sample size is 120 patients for an accrual time of 2 years, an additional follow-up of 1 year, and hazard rates of 0.25 and 0.625 in the risk groups, leading to a probability of an uncensored observation of 0.48 [34] .
PFS was calculated as time from HCT until disease progression or death from any cause, OS was determined as time to death from any cause. PFS and OS rates were estimated and displayed using the Kaplan Meier method. NRM rates were calculated as cumulative incidence rates, considering death due to relapse as a competing event. Differences in NRM were evaluated using Fine and Gray competing risk regression models [35] . Cox proportional hazards models were applied to assess the prognostic value of risk factors on OS and PFS. Results are presented in terms of estimated HRs with two-sided 95% confidence intervals. When possible, we analyzed continuous variables: HRs then describe the risk increase for a one unit change of the prognostic factor. Additionally, Kaplan Meier plots are used to display survival rates when prognostic factors are categorized.
We used univariate Cox regression models as a preliminary assessment. Then, multivariate models were constructed with those factors displaying a univariate p < 0.1, applying a backward variable selection procedure and keeping prognostic factors with p < 0.2 in the model.
We further investigated the prognostic value of followup assessments on OS and PFS by employing these as timedependent covariates in Cox models. These models contain baseline assessment, as well as the change from baseline as prognostic factors, and change from baseline reflects updated assessment values [36] .
In the descriptive analysis of serial assessments, differences (change form baseline) were calculated and compared with Wilcoxon's signed rank test. Further, percentages of patients with a higher/equal/lower or missing value in followup assessments as compared to baseline are presented.
Results

Patient characteristics
The study population included patients ≥ 60 years admitted for alloHCT at the University Hospital Freiburg, Germany between Nov. 2010 and April 2014. The treating physician determined suitability to undergo alloHCT and an appropriate treatment plan independent of CGA/QOL results. Transplant eligibility was not defined by certain cut-off values for functional impairments. Baseline assessments were performed when the final individual decision to transplant was made. There was a median of 14 days between baseline CGA/QOL and alloHCT. The majority (n = 64) patients had CGA/QOL within 30 days of alloHCT. Time variations were mainly due to latency to donor identification; no patient received intensive treatment intermittently. In n = 16 (15,1%) a sibling donor was available. Full baseline data were available for 108 patients. Two patients died prior to alloHCT rendering 106 patients' data for statistical evaluations. Baseline patient characteristics are reported in Table 1 . Patients had myeloid malignancies with only n = 19 (17.9%) in first complete remission (CR1). Accordingly, patients received a high EBMT risk score (median 5 (range 2-7)). Ninety-nine (91.7%) patients received conditioning according to the FBM protocol as described before [33] with slight variations. Nine patients (8.3%) had received one or more previous alloHCTs. The majority (62%) of patients was male with 17.9% of patients living alone. Patients scored high in functional status (independence), resilience and low in comorbidities (HCT-CI ≤ 2: n = 51 (57.5%)). The median Karnofsky Index was 80 with a range from 40-100. Of all patients, 10 (9.3%) did not achieve 100 points in the ADL (Barthel Index) and 33 (30.6%) had impairments in the more sophisticated instrumental ADLs. The vast majority was thus independent according to their own estimation. However, with respect to nutrition, only n = 26 (24%) were not at risk for malnutrition (>11 points). Normal cognition (MMSE ≥ 27) was evident in n = 95 (88%). Three patients required more than 20 s for the up-and-go test indicating a high risk of falls.
The individual's role and social function were markedly below the level of data of e.g., general population data at baseline, resulting in a subjective general estimation for QOL of 58. The most overt symptoms were fatigue and dyspnea (Table 1) .
Sequential assessments
Changes from baseline were captured to describe post HCT recovery in the individual, disease free patient at day +30, +100, and +180.
The lowest results of all CGA/QOL parameters were obtained at day 30 indicating a high symptom burden and low functionality. There was a consecutive steady recovery thereafter. Representative results are presented in Table 2 (median, range of changes from baseline, Signed Rank Test). Percentages of patients with changed CGA/QOL results are presented in the Supplementary Data File. Resilience and mental status showed the steadiest courses.
Survival
Median PFS was 12.5 months with 38.0% (95% CI: 28.6-47.4) alive and progression free at 2 years; median OS was 15.6 months with 43.9% (95% CI: 34.3-53.4) alive at 2 years. Main cause of death (n = 68) was relapse of the underlying disease (n = 31). NRM (n = 37) was caused by acute GvHD (n = 6), infectious complications (n = 23), and other complications in 8 cases, respectively (Table 3) . 3 a) and b) ).
Prognostic factor analyses of baseline data
Factors with univariate p < 0.1 were included in a multivariate Cox model and subjected to a variable selection procedure. Results are presented in Table 4a , b, showing that age at alloHCT was a predominant prognostic factor, and only performance status quantified as Karnofksy Index retained its impact. In order to assess the relevance of CGA parameters irrespective of age, we repeated the selection procedure without age (Table 4c, d) .
To critically question whether a longer time span (>30 days) between CGA and alloHCT would influence results, multivariate analyses were repeated for n = 64 patients who were assessed within the 30 day window. Results are displayed in Suppl. Data: the EORTC QLQ-C30 item fatigue gained some prognostic importance.
We display Kaplan-Meier curves to illustrate the impact of the categorized GCA/QOL variables (e.g., up-and-go test, ADL) on survival. Of all variables investigated, the most interesting were presented graphically in Fig. 1 . Figure 2a -d show the estimated cumulative incidence rates of NRM according to HCT-CI > 2 or ADL < 100 present, and additionally of the competing event relapse-mortality. Larger NRM rates for patients with HCT-CI > 2 or ADL < 100 are displayed, and in turn the rates for the competing event RM are slightly lower for these patients. NRM differences were statistically significant for HCT-CI< = />2 (p = 0.016), but not for ADL</ = 100 (p = 0.14), as assessed with a Fine and Gray model.
Further analyses were conducted to assess the impact of updated data on GCA/QOL by using them as timedependent covariates in Cox regression models. Results are displayed in Table 4e , f, demonstrating the relevance of many GCA/QOL instruments when actual information obtained during follow-up is considered as well. E.g., a significant effect on OS is observed for baseline subjective estimation of physical functioning (PF) (HR = 0.78, 95% CI 0.68-0.89, p = 0.0002), and a significantly lower HR for each ten point increase in PF documented in a follow-up assessment as well (HR = 0.80, 95% CI 0.73-0.88, p < 0.0001). In comparison, the univariate HR for baseline PF was 0.91 (95% CI 0.81-1.01, p = 0.078). While indicators of acute functionality uniformly had a high prognostic value for both OS and PFS, other geriatric domains (MM, MN) and resilience were not associated with OS or PFS as timedependent covariates (Table 4e, f).
Correlations
Age showed relevant correlations only to HCT-CI (rho = 0.23; p = 0.014). All subjective and objective measures of functionality and QOL were correlated to a high degree (Spearman Correlation coefficients given in Supplementary Data). Neither the EBMT risk score nor chronological age showed correlations with CGA/QOL results.
Discussion
It is important to find tools that help determine who is likely to benefit from alloHCT. The potent antileukemic effect of Signed rank pvalue P = <.0001 P = <.0001
Mini mental status n available data sets Signed rank pvalue P = 0.0003 P = 0.173 P = 0.224 alloHCT must be balanced against treatment related morbidity and mortality, especially for older patients. Over the past decade, utilization and survival after alloHCT have increased in patients 70 years [10, 11] . Decisions to pursue alloHCT demand individualization and attention to disease status, as well as patient-specific aspects. In this context, a number of considerations aligned with older patients' preferences and values in the process of alloHCT decision making have been pointed out by Randall et al. [37] . The overview exemplifies issues of aging that need to be further investigated to properly counsel patients on matters such as functional and cognitive impairment, morbidity, caregiver burden, and distress. Currently, the selection of individuals deemed fit for alloHCT may primarily be based on the clinical judgment of the referring hematologist. Incorporating a geriatric assessment into any pre-treatment management of older cancer patients adds quantifiable and reproducible information to describe what has been referred to as "biological age" and to recognize frailty [38] . A consensus conference defined frailty as "a state of increased vulnerability to stressors due to age-related decline in physiologic reserve across neuromuscular, metabolic, and immune systems" [39] . Many operational definitions include alterations in mobility, strength, endurance, nutrition, and physical activity. One of our main findings was that we had a very homogeneous patient cohort with respect to a severe, mostly acute, myeloid malignancy and alloHCT posed the only reasonable approach for cure; however, despite their highest risk malignancies, patients resembled a group of independent, otherwise nearly uncompromised older individuals, resulting in unexpectedly good GCA/QOL results, suggesting a "low biological age".
Of all parameters investigated in our trial, "chronological age" and co-morbidities had the highest prognostic power in our cohort in standard Cox analyses for OS and PFS. When leaving out age from calculations, Karnofsky Index and comorbidities retained their impact while the more steady variables Mini Nutritional Status and Mini Mental Status gained influence suggesting their relevant part in defining "biological age". Possibly, in old patients whose assessment results imply a young "biological age", their advanced "chronological age" entails a heightened vulnerability towards stressors like alloHCT or disease relapse. The few truly CGQ/QOL-compromised subjects showed a dramatically high NRM. Larger trials may be able to reach patient numbers and statistical power necessary to confirm this finding.
The prevalence of non-frail patients in our cohort was different from certain recent studies where a high number of patients exhibited health vulnerabilities and whose findings suggests that chronological age was of minor prognostic importance [8, 40, 41] .
In contrast to those studies, Muffly et al. [42] investigated alloHCT recipients >50 years and found older age to be adversely prognostic. Moreover, limitations in IADL, slow walk speed, high comorbidity index, low mental health were significantly associated with inferior OS. But a "wellpreserved subjective performance status" had a relatively small impact. In contrast, we saw very significant correlations between subjective and objective measures of baseline functionality (i.e., KI, ADL, IADL, EORTC QLQ C30 physical functioning) in our cohort.
There are limitations to our study. The sample size calculation was based on rather optimistic considerations, assuming large hazard ratios and rather frequent occurrence of frailty as indicated in CGA. This was not always met, e.g., for ADL with 10 patients below 100 points or Up+go with only 3 patients above 20 s. Therefore, a reduction in power must be considered, meaning that we might fail to detect relevant prognostic factors. Our solution to this problem was to use continuous instead of categorized variables, thus having the advantages of an increased power and avoiding a discussion of cut point selection. Similar arguments speak for analyzing OS and PFS in the first place and to consider NRM as an additional endpoint of interest, as power calculations rest on the number of events: these are 66/70 for OS/PFS, but only 37 for NRM. Future investigations will benefit from including composite endpoints such as GvHD-, and/or treatment-free survival as meanwhile it is known that alloHCT recipients are subject to many comorbidites among which the most significant, affecting QOL, are acute and chronic GvHD [43] .
Finally, some unanswered questions were beyond the scope of our study: Should CGA/QOL be performed in patients <60 years? Can one distinguish impairments provoked by truly geriatric issues (the age-related decline in physiologic reserves) from reduced functionality as a result of disease (or treatment)?
We followed the approach to assess patients for their "biological age" or signs of frailty when the decision to transplant was made, the assumingly most relevant time to investigate prior to alloHC. As a consequence, we do see a certain variation in time elapsed from baseline assessment to alloHCT. However, analyses of patients transplanted shortly after the assessment differed only in that EORTC QLQ-C30 fatigue gained prognostic importance.
We then investigated in depth CGA/QOL variables as time-dependent co-variables. Regression analyses of repetitive assessments revealed a very strong prognostic value of parameters sensitive to acute change. This can best be seen in assessments of functionality as opposed to resilience or even mental status that showed a rather steady course and had a lower impact on outcome. Further investigations will have to validate the value of serial assessments. The updated CGA/QOL scores reveal a much stronger impact on OS and PFS than baseline information. This certainly poses a very relevant finding in our prognostic factor research. However, the value may not only lie in predicting alloHCT survival in the face of the aging process, but perhaps even more importantly, in pointing out options for "ad hoc GCA tailored" supportive interventions.
Whilst others found indications that attempts to quantify frailty not always lead to improved outcome prediction (44) and that clinical judgment might still be the best instrument available to assess the needs of an individual patient [35] , our novel results for the first time underline the importance of serial assessments and the addition of patient-reported outcome measures (e.g., QOL questionnaires) for risk analyses.
Myeloid malignancies in older patients require intensive treatment if cure is the goal. The question of individually best decision-making still rings true for our older alloHCT candidates: Should one pursue therapy for curative intent and potentially sacrifice their quantity or quality of life? Reassuringly, survivors rated their quality of life as "good" after half a year and were able to return to an independent life.
Results underline that basic information reflecting patient's functionality (KI, ADL), physiologic reserves ("biological age") and QOL may portend outcome. In addition, serial CGA/QOL confer independent prognostic utility and may help us characterize the heterogeneous posttransplant recovery. Overall, patients above 60 years of age deemed fit for RIC alloHCT showed good outcomes and survivors recuperated well after half a year; yet, in this population, increasing "chronological age" was associated with poorer outcome.
